

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Clover Biopharmaceuticals, Ltd.**

**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

## **TERMINATION OF DISCLOSABLE TRANSACTION IN RELATION TO THE LEASE AGREEMENT**

Reference is made to the announcement (the “**Announcement**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated November 26, 2021 in relation to the disclosable transaction for the acquisition of right-of-use assets pursuant to the Lease Agreement entered into between Shanghai Clover as the tenant and Shanghai Pinjiasheng as the landlord (together the “**Parties**”) for office use and R&D laboratory (the “**Shanghai R&D Center**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

Pursuant to the Lease Agreement, the Term should have commenced from May 1, 2022. However, due to the outbreak of COVID-19 epidemic in Shanghai in the first half of 2022, the commencement date of the Term was postponed after arm’s length negotiation between the Parties. In June 2022, the Company decided to reprioritize resources for the regulatory submission and commercialization of SCB-2019 (CpG 1018/Alum), and as a part of which, the Company proposed to exit the Shanghai R&D Center before the commencement of the Term.

The Board announces that pursuant to an agreement (the “**Termination Agreement**”) dated October 14, 2022 entered into between the Parties, the Parties agreed to terminate the Lease Agreement effective from the date of the Termination Agreement.

Pursuant to the Termination Agreement, Shanghai Clover shall surrender the tenancy under the Lease Agreement and shall pay a total of RMB658,721 (the “**Remaining Termination Fee**”) by cash to Pinjiasheng in addition to the security deposit and the two-month rent prepayment (please refer to the interim results announcement of the Company for the six months ended June 30, 2022 dated August 24, 2022 for the impairment losses incurred by the proposed exit of the Shanghai R&D Center) which is to be deducted by Pinjiasheng, as compensation for the early termination of the Lease Agreement, including but not limited to the rent and property management fee for the anticipated vacancy period of the Premises and the reinstatement cost in relation to the Premises. The Parties agreed that, after the settlement of the Remaining Termination Fee, all outstanding matters and potential disputes arising from or relating to the Lease Agreement are settled and neither Party is entitled to raise any proposition, requirement, claim, litigation or arbitration in any nature relating to the Lease Agreement.

The exit of the Shanghai R&D center was before the commencement of the Term, therefore, the right-of-use assets in respect of the Premises were never recognized by the Company and the Termination Agreement does not constitute a disposal of assets. The Board considers that the termination of the Lease Agreement will not have any material impact on the financial position and operation of the Group and is in the interests of the Company and the Shareholders as a whole.

This announcement is published by the Company pursuant to Rule 14.36 of the Listing Rules as the termination of the Lease Agreement constitutes the termination of a previous transaction announced under Chapter 14 of the Listing Rules.

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, October 14, 2022

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Dong LYU, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*